Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co in Multiple Transactions
SEC Form 4 Filing
Lilly Endowment Inc. sold 8,848 shares of Eli Lilly & Co. common stock in multiple transactions on July 3, 2024, at weighted average prices ranging from $915.144 to $917.726.
Summary
- Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., reported the sale of 8,848 shares of common stock on July 3, 2024.
- The sales were executed in multiple transactions with weighted average prices of $915.144, $916.213, and $917.726 per share.
- The total number of shares owned by Lilly Endowment Inc. after these transactions is 97,299,772.
- The transactions were reported on a Form 4 filing with the Securities and Exchange Commission.
Sentiment
Score: 5
Explanation: The document is a neutral report of a share sale, with no indication of positive or negative sentiment. It is a routine filing.
Industry Context
This is a routine disclosure of a significant shareholder's transactions, which is common in the pharmaceutical industry. Such transactions can sometimes influence market sentiment but are often part of normal portfolio management.
Comparison to Industry Standards
- Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders in publicly traded companies, including those in the pharmaceutical sector like Eli Lilly & Co.
- The reported transactions are similar to those of other large institutional investors who periodically adjust their holdings in response to market conditions or investment strategies.
- The volume of shares sold is relatively small compared to the total outstanding shares of Eli Lilly & Co., suggesting it is unlikely to have a significant impact on the overall market.
Stakeholder Impact
- The share sale may have a minor impact on the share price of Eli Lilly & Co., but is unlikely to have a significant impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 07/03/2024 | Date of the share sale transactions. |
Keywords
Lilly Endowment Inc., Eli Lilly & Co, Share Sale, Form 4, Stock Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.